Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering-Plough's Saphris Hits FDA Roadblock With "Complete Response"

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency says there is no need for additional clinical trials for the atypical antipsychotic.

You may also be interested in...



Schering's Antipsychotic Saphris Should Have Easy Advisory Committee Review

Label for asenapine could be highly favorable on weight and adverse event issues given FDA's enthusiasm.

Schering's Antipsychotic Saphris Should Have Easy Advisory Committee Review

Label for asenapine could be highly favorable on weight and adverse event issues given FDA's enthusiasm.

Schering Plough’s Antipsychotic Saphris To Face FDA Panel Review In July

FDA’s Psychopharmacologic Drugs panel will likely consider supplemental data Schering submitted in response to an FDA complete response letter issued in January.

Related Content

Topics

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel